Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
05 août 2022 08h00 HE
|
Nuvectis Pharma, Inc.
NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in...
Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
01 août 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision...
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
27 juil. 2022 08h00 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma Announces FDA Clearance of IND for NXP800
21 juin 2022 08h15 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ,, June 21, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
13 juin 2022 08h30 HE
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
20 mai 2022 10h21 HE
|
Nuvectis Pharma, Inc.
FORT LEE, NJ, May 20, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the...
Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
10 mai 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Dose Escalation Portion of NXP800 Phase 1 Study is Ongoing NXP800 Unique Discovery and Optimization Program Showcased at the 2022 AACR “New Drugs on the Horizon” Session NXP900 Preclinical...
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
13 avr. 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 13, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
11 avr. 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, April 11, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT), (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of precision medicines for...
Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
22 mars 2022 08h30 HE
|
Nuvectis Pharma, Inc.
Completed Initial Public Offering in February 2022, Raising $16.0 million in Gross Proceeds Initiated Phase 1a Clinical Trial for NXP800 Announced Promising Data for NXP900 in Triple Negative...